• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Protagonist Therapeutics Set to Join S&P SmallCap 600

    6/27/24 5:44:00 PM ET
    $PTGX
    $SPGI
    $WIRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $PTGX alert in real time by email

    NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    July 3, 2024

    S&P SmallCap 600

    Addition

    Protagonist Therapeutics

    PTGX

    Health Care



    S&P SmallCap 600

    Deletion

    Encore Wire

    WIRE

    Industrials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/protagonist-therapeutics-set-to-join-sp-smallcap-600-302185154.html

    SOURCE S&P Dow Jones Indices

    Get the next $PTGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTGX
    $SPGI
    $WIRE

    CompanyDatePrice TargetRatingAnalyst
    Protagonist Therapeutics Inc.
    $PTGX
    6/17/2025$72.00Buy
    Citigroup
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    S&P Global Inc.
    $SPGI
    12/20/2024$600.00Buy
    Citigroup
    Protagonist Therapeutics Inc.
    $PTGX
    12/6/2024$47.00Neutral
    Goldman
    Protagonist Therapeutics Inc.
    $PTGX
    12/6/2024$62.00Outperform
    BMO Capital Markets
    Protagonist Therapeutics Inc.
    $PTGX
    11/5/2024$58.00Outperform
    Wedbush
    S&P Global Inc.
    $SPGI
    10/2/2024$599.00Outperform
    Evercore ISI
    More analyst ratings

    $PTGX
    $SPGI
    $WIRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • APi Group Set to Join S&P MidCap 400

      NEW YORK, June 18, 2025 /PRNewswire/ -- APi Group Corp. (NYSE:APG) will replace United States Steel Corp. (NYSE:X) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, June 24. Nippon Steel Corp. (TSE: 5401) acquired United States Steel in a deal that closed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date  Index Name  Action  Company Name  Ticker  GICS Sector   June 24, 2025   S&P MidCap 400  Addition  APi Group   APG  Industrials   June 24, 2025   S&P MidCap 400  Deletion  United States Steel  X  Materials  For more information about S&P Dow Jones Indices, please visit www.spdji.com

      6/18/25 5:46:00 PM ET
      $APG
      $SPGI
      $X
      Engineering & Construction
      Consumer Discretionary
      Finance: Consumer Services
      Finance
    • S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

      TORONTO, June 17, 2025 /CNW/ - Following the completion of the plan of arrangement between Equinox Gold (TSX:EQX) and Calibre Mining (TSX:CXB) resulting in the combination of the two companies. Each share of Calibre Mining will be exchanged for 0.35 new Equinox Gold shares. In expectation of final closing conditions being met, Calibre Mining's shares will be removed from the S&P/TSX Composite Index prior to the open of trading on June 23, 2025. The shares outstanding of Equinox Gold will be increased at the same time to reflect the issuance of shares. For more information about S&P Dow Jones Indices, please visit www.spdji.com ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the largest

      6/17/25 5:15:00 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • Anomali Appoints George Moser as Chief Growth Officer

      Former CISO at S&P Global and Head of Global Operations at Visa Joins Anomali to Help Customers Modernize & Transform Their Security and IT Operations Anomali, the leading AI-Powered Security and IT Operations Platform, today announced the appointment of George Moser as Chief Growth Officer. Moser brings more than two decades of experience leading security and IT transformations at institutions like S&P Global (NYSE:SPGI), Visa (NYSE:V) and Bank of New York Mellon (NYSE:BK). At each organization, Moser elevated security and IT teams to the C-suite and the board of directors and delivered transformations that modernized operations while increasing "EPS" (Earnings per Share) and reducing

      6/16/25 9:00:00 AM ET
      $BK
      $SPGI
      $V
      Major Banks
      Finance
      Finance: Consumer Services
      Business Services

    $PTGX
    $SPGI
    $WIRE
    Leadership Updates

    Live Leadership Updates

    See more
    • APi Group Set to Join S&P MidCap 400

      NEW YORK, June 18, 2025 /PRNewswire/ -- APi Group Corp. (NYSE:APG) will replace United States Steel Corp. (NYSE:X) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, June 24. Nippon Steel Corp. (TSE: 5401) acquired United States Steel in a deal that closed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date  Index Name  Action  Company Name  Ticker  GICS Sector   June 24, 2025   S&P MidCap 400  Addition  APi Group   APG  Industrials   June 24, 2025   S&P MidCap 400  Deletion  United States Steel  X  Materials  For more information about S&P Dow Jones Indices, please visit www.spdji.com

      6/18/25 5:46:00 PM ET
      $APG
      $SPGI
      $X
      Engineering & Construction
      Consumer Discretionary
      Finance: Consumer Services
      Finance
    • Anomali Appoints George Moser as Chief Growth Officer

      Former CISO at S&P Global and Head of Global Operations at Visa Joins Anomali to Help Customers Modernize & Transform Their Security and IT Operations Anomali, the leading AI-Powered Security and IT Operations Platform, today announced the appointment of George Moser as Chief Growth Officer. Moser brings more than two decades of experience leading security and IT transformations at institutions like S&P Global (NYSE:SPGI), Visa (NYSE:V) and Bank of New York Mellon (NYSE:BK). At each organization, Moser elevated security and IT teams to the C-suite and the board of directors and delivered transformations that modernized operations while increasing "EPS" (Earnings per Share) and reducing

      6/16/25 9:00:00 AM ET
      $BK
      $SPGI
      $V
      Major Banks
      Finance
      Finance: Consumer Services
      Business Services
    • Pegasystems Set to Join S&P MidCap 400

      NEW YORK, May 19, 2025 /PRNewswire/ -- Pegasystems Inc. (NASD: PEGA) will replace Nordstrom Inc. (NYSE:JWN) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, May 22. The Nordstrom family and El Puerto de Liverpool S.A.B. de C.V. (BMV:LIVEPOL) are acquiring Nordstrom in a deal expected to be completed on May 20. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector May 22, 2025 S&P MidCap 400 Addition Pegasystems PEGA Information Technology May 22, 2025 S&P MidCap 400 Deletion Nordstrom JWN Consumer Discretionary For more information abou

      5/19/25 6:17:00 PM ET
      $JWN
      $PEGA
      $SPGI
      Clothing/Shoe/Accessory Stores
      Consumer Discretionary
      EDP Services
      Technology

    $PTGX
    $SPGI
    $WIRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Protagonist Therapeutics with a new price target

      Citigroup initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $72.00

      6/17/25 7:50:36 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on S&P Global with a new price target

      BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $600.00

      4/10/25 8:19:38 AM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • Mizuho initiated coverage on S&P Global with a new price target

      Mizuho initiated coverage of S&P Global with a rating of Outperform and set a new price target of $599.00

      3/12/25 7:34:28 AM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $PTGX
    $SPGI
    $WIRE
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Protagonist Therapeutics Inc.

      SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)

      6/16/25 5:30:24 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Protagonist Therapeutics Inc.

      SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)

      5/13/25 12:10:05 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by S&P Global Inc.

      144 - S&P Global Inc. (0000064040) (Subject)

      5/12/25 4:55:32 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $PTGX
    $SPGI
    $WIRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Patel Dinesh V Ph D gifted 1,355 shares, decreasing direct ownership by 0.24% to 562,905 units (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      6/17/25 4:01:12 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Molina Arturo Md exercised 20,000 shares at a strike of $8.04 and sold $1,125,400 worth of shares (20,000 units at $56.27) (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      6/11/25 5:40:40 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Client Officer Moore Sally sold $255,148 worth of shares (500 units at $510.43), decreasing direct ownership by 9% to 5,131 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      5/7/25 5:33:08 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $PTGX
    $SPGI
    $WIRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      6/17/24 4:04:40 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $PTGX
    $SPGI
    $WIRE
    Financials

    Live finance-specific insights

    See more
    • S&P Global Completes Acquisition of TeraHelix, strengthening advanced data modelling and linking capabilities

      Acquisition builds on prior partnership that delivered Gearbox, an LLM-powered linking tool that enhances S&P Global's ability to serve customer AI needs NEW YORK, June 9, 2025 /PRNewswire/ -- S&P Global (NYSE: SPGI), today announced the successful acquisition of TeraHelix, a privately held financial technology firm. TeraHelix helps solve complex, enterprise-scale data challenges by providing frameworks that structure data models for smooth interoperability across platforms, systems and storage architectures. This acquisition strengthens S&P Global's customer-centric approach

      6/9/25 4:01:00 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

      Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

      6/1/25 8:00:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • S&P Dow Jones Indices Announces Change to the S&P/TSX Canadian Dividend Aristocrats Index

      TORONTO, May 23, 2025 /CNW/ - S&P Dow Jones Indices announces the following index change to the S&P/TSX Canadian Dividend Aristocrats Index as a result of the monthly dividend review. Change will be effective prior to the open of trading on Monday, June 2, 2025. S&P/TSX Canadian Dividend Aristocrats Index – June 2, 2025 Symbol COMPANY DELETED BCE BCE Inc DELETED FSZ Fiera Capital Corporation For more information about S&P Dow Jones Indices, please visit www.spdji.com ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Indu

      5/23/25 5:15:00 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $PTGX
    $SPGI
    $WIRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/14/24 4:27:37 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/12/24 4:51:49 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/4/24 1:22:14 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care